Kite Pharma, Inc. Appoints Adrian Bot, M.D., Ph.D., as Chief Scientific Officer

Published: Jul 11, 2011

LOS ANGELES--(BUSINESS WIRE)--Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, announced today the appointment of Adrian Bot, M.D., Ph.D., as Chief Scientific Officer. Dr. Bot brings over 13 years of experience in the biopharmaceutical industry and expertise in discovery, research and development of active immunotherapies in oncology.

Back to news